Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 6 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) Overview | 8 | 1 |
| Therapeutics Development | 9 | 3 |
| Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) Products under Development by Stage of Development | 9 | 1 |
| Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) Products under Development by Therapy Area | 10 | 1 |
| Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) Products under Development by Indication | 11 | 1 |
| Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) Products under Development by Companies | 14 | 2 |
| Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) Products under Development by Universities/Institutes | 16 | 2 |
| Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) Therapeutics Assessment | 18 | 6 |
| Assessment by Monotherapy/Combination Products | 18 | 1 |
| Assessment by Mechanism of Action | 19 | 1 |
| Assessment by Route of Administration | 20 | 2 |
| Assessment by Molecule Type | 22 | 2 |
| Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) Companies Involved in Therapeutics Development | 24 | 10 |
| AveXis, Inc. | 24 | 1 |
| Bioblast Pharma Ltd. | 25 | 1 |
| F. Hoffmann-La Roche Ltd. | 26 | 1 |
| Genethon | 27 | 1 |
| Genzyme Corporation | 28 | 1 |
| Ionis Pharmaceuticals, Inc. | 29 | 1 |
| Novartis AG | 30 | 1 |
| Sarepta Therapeutics, Inc. | 31 | 1 |
| Voyager Therapeutics, Inc. | 32 | 1 |
| WAVE Life Sciences Ltd. | 33 | 1 |
| Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) Drug Profiles | 34 | 26 |
| ALB-111 Drug Profile | 34 | 1 |
| Antisense Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy Drug Profile | 35 | 1 |
| AVXS-101 Drug Profile | 36 | 3 |
| azithromycin Drug Profile | 39 | 1 |
| Gene Therapy to Activate SMN for Spinal Muscular Atrophy Drug Profile | 40 | 1 |
| Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy Drug Profile | 41 | 1 |
| Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy Drug Profile | 42 | 1 |
| LMI-070 Drug Profile | 43 | 1 |
| nusinersen Drug Profile | 44 | 6 |
| Oligonucleotides to Activate SMN2 for Spinal Muscular Atrophy Drug Profile | 50 | 1 |
| PMO-25 Drug Profile | 51 | 1 |
| RG-7800 Drug Profile | 52 | 2 |
| RG-7916 Drug Profile | 54 | 1 |
| Small Molecules for Spinal Muscular Atrophy Drug Profile | 55 | 1 |
| Small Molecules to Activate SMN2 for Spinal Muscular Atrophy Drug Profile | 56 | 1 |
| Small Molecules to Activate SMN2 for Spinal Muscular Atrophy Drug Profile | 57 | 1 |
| Small Molecules to Activate Survival Motor Neuron Protein for Spinal Muscular Atrophy Drug Profile | 58 | 1 |
| VYSMN-101 Drug Profile | 59 | 1 |
| Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) Dormant Projects | 60 | 1 |
| Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) Featured News &Press Releases | 61 | 14 |
| May 16, 2016: AveXis Presents Pulmonary Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1 | 61 | 1 |
| May 06, 2016: AveXis Reports Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1 | 62 | 2 |
| Apr 25, 2016: AveXis to Report Data from Ongoing Phase 1 Clinical Trial of AVXS-101 in Spinal Muscular Atrophy Type 1 | 64 | 1 |
| Apr 21, 2016: Ionis Pharmaceuticals Reports Data Update from Nusinersen Phase 2 Study in Infants with Spinal Muscular Atrophy and Reviews Neurological Disease Franchise | 64 | 1 |
| Mar 31, 2016: Ionis Pharmaceuticals Advances Nusinersen in the Ongoing SHINE Study in Patients with SMA | 65 | 1 |
| Jan 12, 2016: Ionis Pharmaceuticals Completes Target Enrollment for Nusinersen Phase 3 Study, CHERISH, in Children with Spinal Muscular Atrophy | 66 | 1 |
| Jan 07, 2016: Spinal Muscular Atrophy Program Advances with Additional Product Candidate Entering Clinical Development | 67 | 1 |
| Jan 04, 2016: AveXis Announces Completed Enrollment of Phase 1 Clinical Trial for AVXS-101 in Spinal Muscular Atrophy Type 1 | 67 | 1 |
| Oct 15, 2015: Isis Pharmaceuticals Initiates SHINE Study to Provide ISIS-SMN for Patients With SMA Who Have Completed the Phase 3 ENDEAR and CHERISH Studies | 68 | 1 |
| Oct 05, 2015: Data from Ongoing Study of AVXS-101 in Spinal Muscular Atrophy Type 1 Presented at World Muscle Congress | 69 | 1 |
| Oct 04, 2015: Phase 2 Data from Spinal Muscular Atrophy Program Presented at the 20th International Annual Congress of the World Muscle Society | 70 | 1 |
| Jul 14, 2015: Isis Pharmaceuticals Earns $2.15M for Advancing ISIS-SMN in Children With Spinal Muscular Atrophy | 71 | 1 |
| Jun 23, 2015: AveXis Gains Orphan Drug Designation From the European Medicines Agency for Gene Therapy Treatment in Spinal Muscular Atrophy | 72 | 1 |
| Jun 22, 2015: Isis Pharmaceuticals Reports Data from ISIS-SMN Rx in Children with Spinal Muscular Atrophy | 72 | 1 |
| Jun 22, 2015: BioBlast Announces Positive Preclinical Proof-Of-Concept Results Of Its Novel Read- through Platform in Spinal Muscular Atrophy | 73 | 2 |
| Appendix | 75 | 2 |
| Methodology | 75 | 1 |
| Coverage | 75 | 1 |
| Secondary Research | 75 | 1 |
| Primary Research | 75 | 1 |
| Expert Panel Validation | 75 | 1 |
| Contact Us | 75 | 1 |
| Disclaimer | 76 | 1 |